Structures by: Fernandes P.
Total: 35
Cyclometalated ruthenium complexes from naturally occurring quinones: Studies on their photophysical features, computational details and trypanocidal activity?
C49H39F12N9OP2Ru
New J. Chem. (2017)
a=12.9980(3)Å b=17.7660(4)Å c=24.1930(5)Å
α=90° β=120.5210(10)° γ=90°
10,11-Dihydro-5H-dibenzo(a,d)cycloheptene-5-carboxamide
C16H15NO
CrystEngComm (2008) 10, 1 26
a=5.6491(1)Å b=19.5639(4)Å c=22.0741(5)Å
α=84.2178(13)° β=88.4073(14)° γ=83.6001(13)°
Cytenamide form II
C16H13N1O1
CrystEngComm (2008) 10, 7 811
a=5.8100(2)Å b=19.6315(5)Å c=21.7087(6)Å
α=85.918(2)° β=86.164(2)° γ=84.482(2)°
Cytenamide form I
C16H13N1O1
CrystEngComm (2008) 10, 7 811
a=33.9078(10)Å b=33.9078(10)Å c=5.6754(2)Å
α=90° β=90° γ=120°
Creatine form II
C4H9N3O2
CrystEngComm (2014) 16, 35 8197
a=9.8450(3)Å b=5.8373(2)Å c=11.6698(3)Å
α=90° β=105.723(2)° γ=90°
Creatine formic acid solvate
C4H9N3O2,CH2O2
CrystEngComm (2014) 16, 35 8197
a=17.4929(14)Å b=4.7791(4)Å c=10.1101(8)Å
α=90.00° β=90.00° γ=90.00°
Creatine form I
C4H9N3O2
CrystEngComm (2014) 16, 35 8197
a=11.9450(2)Å b=9.5273(1)Å c=5.3438(1)Å
α=90° β=90° γ=90°
Creatine form II
C4H9N3O2
CrystEngComm (2014) 16, 35 8197
a=9.8450(3)Å b=5.8373(2)Å c=11.6698(3)Å
α=90° β=105.723(2)° γ=90°
Creatine formic acid solvate
C4H9N3O2,CH2O2
CrystEngComm (2014) 16, 35 8197
a=17.4929(14)Å b=4.7791(4)Å c=10.1101(8)Å
α=90.00° β=90.00° γ=90.00°
6-chloro-1,1-dioxo-2H-1,2,4-benzothiadiazine-7-sulfonamide
C7H6ClN3O4S2
Journal of Applied Crystallography (2008) 41, 6 1089-1094
a=4.8481(16)Å b=6.359(2)Å c=8.900(3)Å
α=74.49(3)° β=83.90(3)° γ=80.53(3)°
6-chloro-1,1-dioxo-2H-1,2,4-benzothiadiazine-7-sulfonamide
C7H6ClN3O4S2
Journal of Applied Crystallography (2008) 41, 6 1089-1094
a=4.8619(17)Å b=6.377(2)Å c=8.926(3)Å
α=74.40(3)° β=83.93(3)° γ=80.56(3)°
6-chloro-1,1-dioxo-2H-1,2,4-benzothiadiazine-7-sulfonamide
C7H6ClN3O4S2
Journal of Applied Crystallography (2008) 41, 6 1089-1094
a=4.8707(9)Å b=6.3951(12)Å c=8.9448(16)Å
α=74.368(16)° β=83.786(14)° γ=80.459(15)°
6-chloro-1,1-dioxo-2H-1,2,4-benzothiadiazine-7-sulfonamide
C7H6ClN3O4S2
Journal of Applied Crystallography (2008) 41, 6 1089-1094
a=4.8737(9)Å b=6.4046(13)Å c=8.9548(16)Å
α=74.324(17)° β=83.751(15)° γ=80.449(16)°
6-chloro-1,1-dioxo-2H-1,2,4-benzothiadiazine-7-sulfonamide
C7H6ClN3O4S2
Journal of Applied Crystallography (2008) 41, 6 1089-1094
a=4.8786(9)Å b=6.4126(13)Å c=8.9665(16)Å
α=74.266(16)° β=83.693(15)° γ=80.445(16)°
Dibenz[a,c]anthracene
C22H14
Acta Crystallographica Section E (2005) 61, 5 o1483-o1485
a=18.2966(5)Å b=5.06225(10)Å c=15.7245(4)Å
α=90° β=104.5574(15)° γ=90°
3-Azabicyclo[3.3.1]nonane-2,4-dione
C8H11N1O2
Acta Crystallographica Section E (2006) 62, 7 o3046-o3048
a=7.67102(18)Å b=10.5483(2)Å c=18.8867(4)Å
α=90° β=95.5800(12)° γ=90°
Hydrochlorothiazide form II
C7H8ClN3O4S2
Acta Crystallographica Section E (2005) 61, 9 o2798-o2800
a=9.4884(5)Å b=8.3334(4)Å c=15.1309(7)Å
α=90° β=113.2087(19)° γ=90°
Chlorothiazide dimethylformamide solvate
C7H6ClN3O4S2,C3H7NO
Acta Crystallographica Section E (2006) 62, 6 o2216-o2218
a=7.9822(4)Å b=8.8830(5)Å c=11.1075(6)Å
α=86.689(3)° β=75.078(3)° γ=73.196(3)°
(R)-1-phenylethylammonium (R)-2-phenylbutyrate
C8H12N,C10H11O2
Acta Crystallographica Section E (2007) 63, 1 o247-o249
a=6.06200(10)Å b=16.7794(3)Å c=16.8881(4)Å
α=90° β=90° γ=90°
Trichlormethiazide
C8H8Cl3N3O4S2
Acta Crystallographica Section E (2007) 63, 9 o3685-o3685
a=8.7881(2)Å b=9.7924(2)Å c=15.8527(3)Å
α=90.00° β=90.00° γ=90.00°
Carbamazepine trifluoroacetic acid solvate
C15H12N2O,C2HF3O2
Acta Crystallographica Section E (2007) 63, 11 o4269-o4269
a=15.0142(4)Å b=5.28710(10)Å c=20.2489(6)Å
α=90.00° β=101.735(3)° γ=90.00°
Urea DMF solvate (3/1)
C3H7NO,3(CH4N2O)
Acta Crystallographica Section E (2007) 63, 12 o4861-o4861
a=7.5246(13)Å b=9.866(4)Å c=10.821(4)Å
α=65.61(4)° β=79.43(2)° γ=70.76(2)°
Dihydrocarbamazepine formamide
C15H14N2O,CH3NO
Acta Crystallographica Section E (2007) 63, 9 o3888-o3889
a=8.4690(4)Å b=9.0215(4)Å c=10.3137(4)Å
α=74.363(3)° β=83.630(3)° γ=70.847(3)°
10,11-Dihydrocarbamazepine--dimethyl sulfoxide (1/1)
C15H14N2O1,C2H6OS
Acta Crystallographica Section E (2007) 63, 9 o3918-o3919
a=10.2696(3)Å b=6.8543(2)Å c=23.3599(6)Å
α=90.00° β=98.932(2)° γ=90.00°
3-azabicyclo[3.3.1]nonane-2,4-dione 1-methylnaphthalene hemisolvate
C8H11NO2,0.5C11H10
Acta Crystallographica Section E (2006) 62, 9 o3752-o3754
a=15.02360(18)Å b=7.32295(12)Å c=22.5164(3)Å
α=90° β=106.0201(6)° γ=90°
10,11-Dihydrocarbamazepine--formic acid (1/1)
C15H14N2O,CH2O2
Acta Crystallographica Section E (2007) 63, 3 o1469-o1470
a=5.2298(4)Å b=9.3849(12)Å c=14.4858(18)Å
α=83.853(5)° β=88.230(7)° γ=88.221(7)°
Hydroflumethiazide dimethylsulfoxide disolvate
C8H8F3N3O4S2,2C2H6OS
Acta Crystallographica Section E (2007) 63, 10 o3956-o3956
a=5.55700(10)Å b=20.8433(4)Å c=17.4142(3)Å
α=90.00° β=93.540(2)° γ=90.00°
Urea--dimethylacetamide
C4H9NO,CH4N2O
Acta Crystallographica Section E (2008) 64, 2 o355-o355
a=7.2770(3)Å b=17.5394(9)Å c=7.3789(4)Å
α=90° β=119.450(3)° γ=90°
10,11-Dihydrocarbamazepine--acetic acid (1/1)
C15H14N2O,C2H4O2
Acta Crystallographica Section E (2006) 62, 12 o5361-o5362
a=5.3104(4)Å b=15.4246(17)Å c=18.732(2)Å
α=90.00° β=95.106(7)° γ=90.00°
(R)-1-phenylethylammonium (R)-2-phenylbutyrate
C8H12N,C10H11O2
Acta Crystallographica Section E (2007) 63, 1 o202-o204
a=11.88215(15)Å b=5.97647(8)Å c=13.07499(15)Å
α=90° β=113.5100(10)° γ=90°
Chlorothiazide DMSO solvate
C7H6ClN3O4S2,C2H6OS
Acta Crystallographica Section E (2007) 63, 5 o2423-o2423
a=9.0965(3)Å b=11.2081(4)Å c=15.8916(5)Å
α=109.009(2)° β=103.384(2)° γ=96.246(2)°
Chlorothiazide N,N-dimethylacetamide solvate
C7H6ClN3O4S2,2C4H9NO
Acta Crystallographica Section E (2007) 63, 5 o2422-o2422
a=8.2037(3)Å b=24.5226(6)Å c=10.6443(3)Å
α=90.00° β=105.231(2)° γ=90.00°
Bendroflumethiazide acetone solvate
C15H14F3N3O4S2,C3H6O
Acta Crystallographica Section C (2007) 63, 11 o659-o663
a=8.192(2)Å b=9.525(2)Å c=14.101(2)Å
α=99.538(17)° β=100.171(17)° γ=100.42(2)°
Bendroflumethiazide N,N-dimethylformamide solvate
C15H14F3N3O4S2,C3H7NO
Acta Crystallographica Section C (2007) 63, 11 o659-o663
a=8.2527(3)Å b=17.8431(7)Å c=14.9012(5)Å
α=90° β=103.752(4)° γ=90°
Creatine form I
C4H9N3O2
CrystEngComm (2014) 16, 35 8197
a=11.9450(2)Å b=9.5273(1)Å c=5.3438(1)Å
α=90° β=90° γ=90°